Which bacterial pathogens are covered by fosfomycin that are not covered by nitrofurantoin (Macrobid)?

Fosfomycin's Expanded Coverage Beyond Nitrofurantoin

Fosfomycin covers vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and extended-spectrum β-lactamase (ESBL)-producing gram-negative rods—organisms that nitrofurantoin (Macrobid) does not reliably cover. 1

Key Bacterial Coverage Differences

Gram-Positive Organisms

Enterococcus faecium (including VRE):

• Fosfomycin demonstrates activity against VRE, including Enterococcus faecium 1, 2
• Nitrofurantoin covers Enterococcus faecalis but has limited activity against E. faecium 3
• For uncomplicated UTIs due to VRE, fosfomycin 3g single dose is specifically recommended 4

Methicillin-Resistant Staphylococcus aureus (MRSA):

• Fosfomycin has in vitro activity against MRSA 1
• Nitrofurantoin covers methicillin-susceptible S. aureus but MRSA coverage is not established 3

Gram-Negative Organisms with Resistance Mechanisms

ESBL-Producing Enterobacterales:

• Fosfomycin maintains excellent activity against ESBL-producing E. coli (95-99% susceptibility) and reasonable activity against ESBL-producing Klebsiella pneumoniae (36-53% susceptibility) 1, 5, 6
• Nitrofurantoin's activity against ESBL producers is limited primarily to E. coli and does not extend reliably to other Enterobacterales 3

Broader Enterobacterales Coverage:

• Fosfomycin covers Enterobacter species (71.5% susceptibility), Proteus species (76.7% susceptibility), Serratia marcescens, and Citrobacter species (91.1% susceptibility) 2, 6, 7, 8
• Nitrofurantoin explicitly has NO activity against most Proteus species or Serratia species 3

Clinical Context and Limitations

When This Matters Most

The expanded coverage of fosfomycin becomes clinically relevant in:

• Multidrug-resistant UTIs: When ESBL-producing organisms or VRE are suspected or confirmed 1, 4
• Treatment failures: When nitrofurantoin has failed and susceptibility testing reveals organisms outside nitrofurantoin's spectrum 3
• Non-E. coli UTIs: Particularly Proteus, Enterobacter, or Serratia species 2, 6

Critical Caveats

Lower bacterial eradication rates: Fosfomycin's bacterial efficacy (80%) is lower than nitrofurantoin's (88-92%), though clinical cure rates are comparable (91% vs 93%) 1

Avoid in pyelonephritis: Both agents should be avoided if early pyelonephritis is suspected, but this is particularly emphasized for fosfomycin due to lower tissue penetration 1

Klebsiella coverage limitations: While fosfomycin covers some Klebsiella strains, susceptibility rates are only 38-53%, making it unreliable for empiric therapy when Klebsiella is suspected 5, 6

Practical Algorithm

Choose fosfomycin over nitrofurantoin when:

1. Patient has known VRE colonization or infection
2. Prior culture shows ESBL-producing organism
3. Prior culture shows Proteus, Enterobacter, or Serratia species
4. Patient has failed nitrofurantoin therapy and culture shows organism outside nitrofurantoin spectrum
5. MRSA UTI is documented (rare but possible)

Choose nitrofurantoin over fosfomycin when:

• Simple E. coli or E. faecalis UTI is suspected (higher bacterial eradication)
• Multi-day therapy is preferred over single-dose
• Cost is a significant concern